Lanterne Dx Completes Merger with Flagship Biosciences, Expanding Biomarker and Digital Pathology CapabilitiesBoulder, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Lanterne Dx, LLC, a discovery and clinical phase CRO offering histopathology and biomarker validation services to pharmaceutical and biotech customers, today announced it has completed its merger with Flagship Biosciences, Inc., a computational biology, data science, and digital pathology company backed by Ampersand Capital Partners. The combined organization will operate under the Lanterne Dx name.
